- Home
- GPOR vs BDTX Comparison
GPOR vs BDTX Comparison
Compare GPOR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPOR | BDTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPOR | BDTX |
|---|---|---|
| Price | $179.47 | $2.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $227.75 | $10.60 |
| AVG Volume (30 Days) | 263.6K | ★ 933.0K |
| Earning Date | 02-24-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $1,231,668,000.00 | $70,000,000.00 |
| Revenue This Year | $57.83 | N/A |
| Revenue Next Year | $9.48 | N/A |
| P/E Ratio | ★ N/A | $7.38 |
| Revenue Growth | ★ 38.91 | N/A |
| 52 Week Low | $153.27 | $1.20 |
| 52 Week High | $225.78 | $4.94 |
Technical Indicators
Market Signals| Indicator | GPOR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 44.27 |
| Support Level | $172.00 | $2.56 |
| Resistance Level | $181.84 | $2.83 |
| Average True Range (ATR) | 6.51 | 0.14 |
| MACD | -2.41 | 0.06 |
| Stochastic Oscillator | 14.70 | 56.47 |
Price Performance
Historical ComparisonAbout GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.